Evidence map›Paper›PMID 32715761›Full record

ArticleAmerican journal of physiology. Renal physiology2020

Virtual measurements of paracellular permeability and chronic inflammation via color coded pixel-wise T

Nishant Singh, Irina Zabbarova, Youko Ikeda, Jodi Maranchie, Christopher Chermansky, Lesley Foley, T Kevin Hitchens, Naoki Yoshimura, Anthony Kanai, Jonathan Kaufman and 1 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of physiology. Renal physiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Color Maps: Facilitating the Clinical Impact of Quantitative MRI.Journal of magnetic resonance imaging : JMRI · 2025
    Review
  2. Article
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Nishant SinghDepartment of Urology, University of Pittsburgh, Pittsburgh, Pennsylvania.
Irina ZabbarovaDepartment of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania.
Youko IkedaDepartment of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania.ORCID 0000-0001-9774-1523
Jodi MaranchieDepartment of Urology, University of Pittsburgh, Pittsburgh, Pennsylvania.
Christopher ChermanskyDepartment of Urology, University of Pittsburgh, Pittsburgh, Pennsylvania.
Lesley FoleyAdvanced Imaging Center, University of Pittsburgh, Pittsburgh, Pennsylvania.
T Kevin HitchensAdvanced Imaging Center, University of Pittsburgh, Pittsburgh, Pennsylvania.
Naoki YoshimuraDepartment of Urology, University of Pittsburgh, Pittsburgh, Pennsylvania.ORCID 0000-0001-8070-1664
Anthony KanaiDepartment of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania.
Jonathan KaufmanLipella Pharmaceuticals, Pittsburgh, Pennsylvania.
Pradeep TyagiDepartment of Urology, University of Pittsburgh, Pittsburgh, Pennsylvania.ORCID 0000-0001-6586-4545
University of Pittsburgh · USLipella Pharmaceuticals (United States) · US

Funding

PDE5 Inhibition of Afferents and Interstitial Cells in Overactive Mouse BladdersR01DK098361 · NIDDK · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI BIRDER, LORI A, KANAI, ANTHONY JOHN · 2014 to 2024
$5.7M
Roles of Nitric Oxide and Superoxide in CystitisR01DK071085 · NIDDK · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI KANAI, ANTHONY JOHN · 2005 to 2017
$3.3M
Preclinical Development of Tacrolimus for Radiation CystitisR44DK102247 · NIDDK · LIPELLA PHARMACEUTICALS, INC. · PI KAUFMAN, JONATHAN H · 2014 to 2016
$1.5M
Phenotyping Interstitial Cystitis/Bladder Pain Syndrome by ICE-MRI Based Bladder Permeability AssayR44DK108397 · NIDDK · LIPELLA PHARMACEUTICALS, INC. · PI KAUFMAN, JONATHAN H · 2022 to 2023
$1.4M
Measuring Bladder Permeability with MRI Using a Novel Contrast Agent FormulationR42DK108397 · NIDDK · LIPELLA PHARMACEUTICALS, INC. · PI KAUFMAN, JONATHAN H · 2018 to 2019
$1.2M
Clinical Development of Tacrolimus for Hemorrhagic CystitisSB1DK102247 · NIDDK · LIPELLA PHARMACEUTICALS, INC. · PI KAUFMAN, JONATHAN H · 2017 to 2018
$998k
Measuring Bladder Permeability with MRI using a Novel Contrast Agent FormulationR41DK108397 · NIDDK · LIPELLA PHARMACEUTICALS, INC. · PI KAUFMAN, JONATHAN H · 2015 to 2015
$225k
NIDDK NIH HHS R01 DK071085NIDDK NIH HHS R01 DK098361NIDDK NIH HHS R41 DK108397NIDDK NIH HHS R42 DK108397NIDDK NIH HHS R44 DK102247NIDDK NIH HHS R44 DK108397NIDDK NIH HHS SB1 DK102247
6 · The paper itself

Abstract

To assess whether quantitative T

Indexed as

AnimalsContrast MediaFemaleInflammationLeukocyte Common AntigensMiceMice, Inbred C57BLOrganometallic CompoundsPermeabilityUrinary BladderUrinary Bladder DiseasesZonula Occludens-1 ProteinContrast MediagadobutrolLeukocyte Common AntigensOrganometallic CompoundsTjp1 protein, mouseZonula Occludens-1 Proteinbladder permeabilitycystitisgadoliniumT1 mappingvirtual histology

Identifiers

PMID32715761
PMCPMC7509285
OpenAlexW3045583163

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.